The global ATP assays market is projected to reach USD 412 million by 2027 from USD 276 million in 2022, at a CAGR of 8.4%. The growth of the ATP assays market is mainly driven by factors such as major investments in R&D of various pharma & biotech products, increase in research-related funding activities by government for supporting innovation and advancements in technologies in the pharmaceutical & biopharmaceutical sector, increasing incidence of chronic diseases, large-scale outsourcing of clinical diagnostic testing by hospitals to commercial service providers, and growth in the personalized medicine and clinical diagnostics. On the other hand, the inability of ATP assays to differentiate between extracellular and intracellular ATP is limiting the market growth to some extent.
The global ATP assays market is consolidated at the top, with various players governing major shares in the market. Some of the major players in the market are Thermo Fisher Scientific, Inc. (US), Promega Corporation (US), Merck KGaA (Germany), PerkinElmer, Inc. (US), Agilent Technologies, Inc. (US), Abcam plc (UK), Lonza Group (Switzerland), NEOGEN Corporation (US), 3M (US), and Danaher Corporation (US).
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific (US), provides scientific instrumentation products, reagents & consumables, and software & services to the healthcare, life science, academic, government, and biotechnology & pharmaceutical sectors. It provides ATP reagents & kits through its Life Science Solutions segment and provides instruments for the ATP assays market through its Analytical Instruments segment. The company operates in more than 50 locations across the globe. It offers services to more than 400,000 customers working in pharmaceutical & biotechnology companies, hospitals & clinical diagnostic laboratories, universities, research institutes & government agencies, and environmental, industrial quality, & process control settings. From January 2018 to February 2022, Thermo Fisher launched the Orbitrap 240 Mass Spectrometer and Q Exactive UHMR Hybrid Quadrupole Orbitrap Mass Spectrometer in the ATP assays product portfolio. The company collaborated with Biognosys, a leading developer of next-generation proteomics solutions, for advanced data-independent acquisition (DIA) mass spectrometry-based workflows.
Merck KGaA (Germany), operates through three business segments, namely, Healthcare, Life Science, and Performance Materials. The Life Science business segment consists of the Merck Millipore business and the acquired life science business of Sigma-Aldrich Corporation (US). Merck provides ATP kits, reagents, and instruments through its Life Science segment. This segment offers a broad portfolio of products and services for customers across the globe. Merck provides ATP assay reagents and kits that are manufactured by Roche Diagnostics as part of its product portfolio under Sigma-Aldrich Corporation (US). The company has a strong geographical presence in 66 countries across the Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa. The company adopts organic growth strategies such as expansions to increase its dominance in this market. Merck broadened its manufacturing footprint with a combined USD 43.97 million (EUR 40 million) investment at its production facilities in Danvers, Massachusetts, and Jaffrey, New Hampshire, US to supply critical products to customers developing lifesaving therapies, including COVID-19 vaccines, as well as provide products and services for biopharmaceutical manufacturing. These expansions will significantly increase capacity and output at these facilities.
PerkinElmer, Inc. (US), is a leading provider of products, services, and solutions to the diagnostics, life sciences, and applied markets. It provides detection, imaging, services, and informatics. The company’s customer base includes pharmaceutical and biotechnology companies and academic research institutes. PerkinElmer has two business segments, namely, Discovery & Analytical Solutions and Diagnostics. PerkinElmer provides ATP assays in the market through its Discovery & Analytical Solutions segment. The company has 20 offices in the US, China, Japan, the UK, Germany, France, and Italy. The company has a diversified product portfolio, and its position in the market is attributed to its active acquisitions for the adoption of advanced technologies. In 2021, it acquired Nexcelom Bioscience (US) to help scientists resolve some of today’s most pressing health challenges through modernizing cell-based assays using the most advanced cell models. Through this acquisition, the company will bring Nexcelom’s expertise and technologies in drug development together with the passion and solutions for drug discovery.
ATP Assays Market by Product (Consumables (Kits, Reagent, Microplate), Instrument (Luminometer, Spectrophotometers)), Application (Contamination, Disease Testing, Drug Discovery), End User (Hospitals, Pharmaceuticals, Food Testing) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE